PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
32061138-0	2020	Expression, mutation, and methylation of crbn-pathway genes at pre- and post-lenalidomide treatment in multiple myeloma.	lenalidomide	77-89	cereblon	Homo sapiens	41-45	
31619706-0	2019	Cereblon gene variants and clinical outcome in multiple myeloma patients treated with lenalidomide.	lenalidomide	86-98	cereblon	Homo sapiens	0-8	
32071327-9	2020	The data here show that thalidomide, lenalidomide, and pomalidomide affect stem cell mesendoderm differentiation through CRBN-mediated degradation of SALL4 and highlight the utility of the LPM differentiation model for studying the teratogenicity of new CRBN modulating agents.	lenalidomide	37-49	cereblon	Homo sapiens	121-125	
32071327-9	2020	The data here show that thalidomide, lenalidomide, and pomalidomide affect stem cell mesendoderm differentiation through CRBN-mediated degradation of SALL4 and highlight the utility of the LPM differentiation model for studying the teratogenicity of new CRBN modulating agents.	lenalidomide	37-49	cereblon	Homo sapiens	254-258	
31859249-3	2020	As an alternative strategy to target AKT, we report the development of INY-03-041, a pan-AKT degrader consisting of the ATP-competitive AKT inhibitor GDC-0068 conjugated to lenalidomide, a recruiter of the E3 ubiquitin ligase substrate adaptor Cereblon (CRBN).	lenalidomide	173-185	cereblon	Homo sapiens	244-252	
31859249-3	2020	As an alternative strategy to target AKT, we report the development of INY-03-041, a pan-AKT degrader consisting of the ATP-competitive AKT inhibitor GDC-0068 conjugated to lenalidomide, a recruiter of the E3 ubiquitin ligase substrate adaptor Cereblon (CRBN).	lenalidomide	173-185	cereblon	Homo sapiens	254-258	
31619706-2	2019	Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy.	lenalidomide	50-62	cereblon	Homo sapiens	0-8	
31619706-2	2019	Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy.	lenalidomide	50-62	cereblon	Homo sapiens	10-14	
31619706-2	2019	Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy.	lenalidomide	123-135	cereblon	Homo sapiens	0-8	
31619706-2	2019	Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy.	lenalidomide	123-135	cereblon	Homo sapiens	10-14	
31619706-2	2019	Cereblon (CRBN) is the direct molecular target of lenalidomide and genetic polymorphisms in CRBN have been associated with lenalidomide efficacy.	lenalidomide	123-135	cereblon	Homo sapiens	92-96	
31619706-3	2019	In this study, we assessed the correlation of five single nucleotide variants (SNVs) in the CRBN gene with clinical response and outcomes in patients with NDMM administered KRd therapy with lenalidomide maintenance, achieving favorable trial endpoints in a prospective Phase II study (NCT01402284).	lenalidomide	190-202	cereblon	Homo sapiens	92-96